TW200621998A - Method - Google Patents

Method

Info

Publication number
TW200621998A
TW200621998A TW094125025A TW94125025A TW200621998A TW 200621998 A TW200621998 A TW 200621998A TW 094125025 A TW094125025 A TW 094125025A TW 94125025 A TW94125025 A TW 94125025A TW 200621998 A TW200621998 A TW 200621998A
Authority
TW
Taiwan
Prior art keywords
mammal
erbb receptor
receptor drug
kiaa0931
etr101
Prior art date
Application number
TW094125025A
Other languages
English (en)
Inventor
Kevin Hudson
Gayle Marshall
Mehran Sam
Marie Caroline South
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200621998A publication Critical patent/TW200621998A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW094125025A 2004-07-23 2005-07-22 Method TW200621998A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59035704P 2004-07-23 2004-07-23
US61902704P 2004-10-18 2004-10-18

Publications (1)

Publication Number Publication Date
TW200621998A true TW200621998A (en) 2006-07-01

Family

ID=35107052

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094125025A TW200621998A (en) 2004-07-23 2005-07-22 Method

Country Status (11)

Country Link
US (1) US20080286771A1 (zh)
EP (1) EP1781815A2 (zh)
JP (1) JP2008507264A (zh)
AU (1) AU2005263972A1 (zh)
BR (1) BRPI0513589A (zh)
CA (1) CA2574311A1 (zh)
IL (1) IL180333A0 (zh)
MX (1) MX2007000944A (zh)
NO (1) NO20070721L (zh)
TW (1) TW200621998A (zh)
WO (1) WO2006008526A2 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1848414T3 (pl) 2005-02-03 2011-10-31 Wyeth Llc Sposób leczenia nowotworu opornego na gefitinib
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
WO2007101122A2 (en) * 2006-02-24 2007-09-07 University Of Chicago Methods and compositions involving slc17a1
US8486903B2 (en) 2007-10-04 2013-07-16 Agency For Science, Technology And Research (A*Star) TAZ/WWTR1 for diagnosis and treatment of cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20130331294A1 (en) * 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
CN102202667A (zh) 2008-08-04 2011-09-28 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
MX356593B (es) 2009-04-06 2018-06-05 Wyeth Llc Régimen de tratamiento que utiliza neratinib para cáncer de mama.
KR20140044341A (ko) * 2011-06-02 2014-04-14 알막 다이아그노스틱스 리미티드 암에 대한 분자적 진단 검사
KR20150090246A (ko) 2012-12-03 2015-08-05 알막 다이아그노스틱스 리미티드 암을 위한 분자 진단 테스트
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1837025A3 (en) * 2002-06-05 2007-12-19 Cedars-Sinai Medical Center Method of treating cancer using kinase inhibitors
EP1735463A4 (en) * 2004-03-26 2008-10-15 Bristol Myers Squibb Pharma Co BIOMARKERS AND METHOD FOR DETERMINING SENSITIVITY AGAINST MODULATORS OF EPIDERMAL GROWTH FACTOR RECEPTOR IN NON-SMALL CELL LUNG CANCER

Also Published As

Publication number Publication date
US20080286771A1 (en) 2008-11-20
AU2005263972A1 (en) 2006-01-26
NO20070721L (no) 2007-04-20
EP1781815A2 (en) 2007-05-09
WO2006008526A3 (en) 2006-07-13
BRPI0513589A (pt) 2008-05-13
IL180333A0 (en) 2007-07-04
WO2006008526A2 (en) 2006-01-26
MX2007000944A (es) 2007-04-13
CA2574311A1 (en) 2006-01-26
JP2008507264A (ja) 2008-03-13

Similar Documents

Publication Publication Date Title
TW200621998A (en) Method
Angers et al. Environmentally induced phenotypes and DNA methylation: how to deal with unpredictable conditions until the next generation and after
WO2007113532A3 (en) Prediction of heterosis and other traits by transcriptome analysis
EP2487257A3 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
MX2023005326A (es) Composiciones de oligonucleótidos y métodos de las mismas.
MX2010002113A (es) Metodos para detectar oligonucleotidos.
EP2420840A3 (en) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
WO2008140793A3 (en) Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
GB2452437A (en) Evaluating genetic disorders
WO2009117122A3 (en) Genetic analysis
MX2010006576A (es) Composiciones y metodos para producir isopreno.
CO6351830A2 (es) Método para caracterizar secuencias en muestras de material genético
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
GB2456390A (en) Bipolar disorder treatments
NZ591613A (en) Polymorphic marker rs965513 for risk assessment of thyroid cancer
WO2007035814A3 (en) Reagents, methods and kits for classification of fungi and direction of anti-fungal therapy
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
DE502006007526D1 (de) Antimikrobielles medizintechnisches produkt, verfahren zu seiner herstellung und verwendung
WO2006131537A3 (en) Methods for the diagnosis of immune graft tolerance
EP1764419A3 (en) Detecting gene methylation for diagnosis of a proliferative disorder
EP1987165A4 (en) Gene with influence on the human memory
WO2012030983A3 (en) Variability single nucleotide polymorphisms linking stochastic epigenetic variation and common disease
EP2730663A3 (en) Genetic factors associated with inhibitor development in hemophilia A
WO2008137089A3 (en) Gene signature of early hypoxia to predict patient survival